A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
Recruiting now
Conditions studied: HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT
In brief
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.
Key facts
- Study ID
- NCT07351669
- Run by
- Zhongda Hospital
- People needed
- 121
- Starts
- 2026-01-20
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2026-06-10
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- age 18-75 years;
- diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;
- Barcelona Clinic Liver Cancer (BCLC) stage A or B;
- prior treatment with TACE;
- undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;
- undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort);
- informed consent.
You may not qualify if…
- contraindications to contrast-enhanced CT or MRI;
- presence of extrahepatic malignancy;
- poor image quality or incomplete clinical data;
- lack of regular CT or MRI follow-up in non-surgical cohort;
- withdrawal from the study.
Where it is running
- Zhongda Hospital Southeast University — Nanjing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.